← Back to Search

Macrolide Antibiotic

Treatment eye for Meibomian Gland Dysfunction

Phase 2
Waitlist Available
Led By Brad H Feldman, MD
Research Sponsored by Philadelphia Eye Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2,4 and 6 weeks
Awards & highlights

Summary

The purpose of this study is to evaluate the effect of Azasite on patients with corneal surface irregularity (meibomian gland dysfunction).

Eligible Conditions
  • Meibomian Gland Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2,4 and 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2,4 and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Astigmatism
Best corrected distance visual acuity
Change in Corneal Irregularity Measurement
+4 more
Other study objectives
Tear film break-up time

Side effects data

From 2022 Phase 4 trial • 42 Patients • NCT05027516
9%
pain at injection site
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rocephine®
Rocephine® + Azithromycin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment eyeExperimental Treatment1 Intervention
Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
Group II: DurasitePlacebo Group1 Intervention
Vehicle of Azasite used as placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Azithromycin
FDA approved

Find a Location

Who is running the clinical trial?

Philadelphia Eye AssociatesLead Sponsor
1 Previous Clinical Trials
51 Total Patients Enrolled
Thomas Jefferson UniversityOTHER
460 Previous Clinical Trials
150,361 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,978 Previous Clinical Trials
5,178,047 Total Patients Enrolled
~0 spots leftby Oct 2025